UCF | Environmental Health and Safety
UNIVERSITY OF CENTRAL FLORIDA

SAFETY Meeting Minutes
IBC Committee
Zoom

MEETING TIME RECORDS

Meeting start time: 7/9/2025 3:01 PM
Meeting end time: 4:04 PM

VOTING MEMBER ATTENDANCE

Name of Regular/Alternate Member	Status (Member or Alternate)	Present by Teleconference?
Karl McKinstry	Member	X
Gregory Danyluk	Member	X
Melina Kinsey	Member	X
Kyle Rohde	Chair – Member	X
Stanley Haimes	Member	Absent
Hubert Salvail	Member	X
Judith Hecker	Member	X
Lane Coffee	Vice-Chair – Member	X
Yulia Gerasimova	Member	X
Teresa Krisch	Member	X

QUORUM INFORMATION

Number of SAFETY members on the roster: 9
Number required for quorum: 5

All members present by teleconference received all pertinent material before the meeting and were able to actively and equally participate in all discussions.

ATTENDANCE STATUS AND VOTING KEY

ABSTAIN:	Present for the vote, but not voting "For" or "Against."
ABSENT:	Absent for discussion and voting for reasons other than a conflicting interest.
RECUSED:	Absent from the meeting during discussion and voting because of a conflicting interest.
SUBSTITUTION:	When regular members and their alternate(s) are listed in the ATTENDANCE table above and an alternate member substitutes for the regular member this identifies the name of the alternate to indicate which

	individual is serving as the voting member for this vote. May be deleted if there are no substitutions.

GUEST NAMES **Sophia Vermeulen – Biosafety Specialist**

Previous Meeting minutes approved: Yes June 2025 Minutes Approved
Move: Lane Coffee
Second: Karl McKinstry
Votes:

For:	9
Against:	0
Recused:	0
Absent:	1
Abstained:	0

REVIEW OF SUBMISSIONS

De Novo Review

1. Review of SPROTO202500000008

Title:	Analysis of SARS-CoV-2 RNA - Gerasimova
Investigator:	Yulia Gerasimova
Submission ID	SPROTO202500000008
Funding:	• Name: University of Central Florida Research Foundation, Inc., Grant Office ID: , Funding Source ID:
Documents Reviewed:	None
Agents:	
Agent Characteristics:	
Agent Containment:	
Applicable NIH Guidelines:	None

a. **Determination:** Modifications Required
Move: Lane Coffee
Second: Judy Hecker

b. **Required modifications:**
   1. Summary of Research - Need a short, high-level overview of the research performed. Avoid use of acronyms and scientific jargon. Please include: The central questions the research is intended to answer; the primary objectives and overview of all methods or approaches used.
   2. Protocol Team Members – Please include all team members who will be working on this protocol.
   3. Biosafety Summary – Question 2; Need statement and/or add a certificate from BEI stating the Viral RNA from BEI is virus free. Can add certificate to the Supporting documents section.
   4. Exposure Assessment and Protective Equipment – Question 1; If have BEI certificate of viral RNA being virus free, then the statement on questions 1 needs to be altered.

c. **Votes:**

For:	8
Against:	0
Recused:	1 Gerasimova
Absent:	1
Abstained:	0

De Novo Review

2. Review of SPROTO202500000009

Title:	Melatonin and Inflammation - Wells
Investigator:	Adam Wells
Submission ID	SPROTO202500000009
Funding:	• Name: UCF/Office of Research, Grant Office ID: 0000007553, Funding Source ID:
Documents Reviewed:	• BARA 18-25 • NCE
Agents:	• Human Derived Blood and Blood Types
Agent Characteristics:	Biological Agent Sources: • Human research participants as part of IRB approved study
Agent Containment:	Biological Containment Levels: • Human Derived Blood and Blood Types: BSL-2
Applicable NIH Guidelines:	None

a. **Determination:** Modifications Required

Move: Melina Kinsey
Second: Lane Coffee

b. **Required modifications:**
1. Exposure Assessment and Protective Equipment – "Direct students to seek treatment immediately at UCF Student Health." Please clarify if "students" refers to students working on the protocol or students which are donors of the blood being collected.
2. Tissues, Blood, or Body Fluids – Human Derived Blood and Blood types;
   a. Biology building lab 224 not listed in protocol under storage/usage location – listed in the "Describe the use of the agent" section. Only the education complex lab is listed in usage/storage location.
   b. Add the transport procedure for moving samples collected in the Education Complex & Gym to the Biology Building lab 224.

c. **Votes:**

For:	9
Against:	0
Recused:	0
Absent:	1
Abstained:	0

De Novo Review

3. Review of SPROTO202500000010

Title:	Studying resistant human pathogens - Fleeman
Investigator:	Renee Fleeman
Submission ID	SPROTO202500000010
Funding:	• Name: National Institutes of Health (NIH), Grant Office ID: AWD00005521, Funding Source ID: 4R00AI163295-03 • Name: University of Central Florida Research Foundation, Inc., Grant Office ID: , Funding Source ID:
Documents Reviewed:	• Flow cytometry sorting safety • hvKp antibiotic sensitivity.pdf • PFA is highly permeable to tissues.pdf • Poster of sorting pathogens safely • Hypermucoviscous K. Pneumoniae NTUH antibiotic susceptibility.pdf • Springer Paraformaldehyde fixation protocols.pdf

	• FEMS flow sorting review.pdf • Formaldehyde and Paraformaldehyde SOP_SL updated.pdf • Tularemia • Paper describing F. tularensis novicida U112 as a BSL-2 surrogate • NIH_NOA_4R00AI163295-03.pdf • MigrationPlaceholder • MigrationPlaceholder
Agents:	• Burkholderia thailandensis • Francisella tularensis • Acinetobacter baumannii • Bacillus subtilis • Escherichia coli K12 or derivative • Klebsiella pneumoniae • Pseudomonas aeruginosa • Staphylococcus aureus • Vibrio cholerae • Respiratory Tissue • Human Derived Blood and Blood Types • Non Human Derived Blood and Blood Types • A-549 • HEP-G2 • Enterobacter cloacae complex • 293T • HekBlue hTLR4 reporter cells • J774A.1 murine-derived macrophages • Burkholderia cepacia
Agent Containment:	Biological Containment Levels: • J774A.1 murine-derived macrophages: BSL-1 • Pseudomonas aeruginosa: BSL-2 • Acinetobacter baumannii : BSL-2 • Bacillus subtilis : BSL-1 • Escherichia coli K12 or derivative: BSL-1 • Klebsiella pneumoniae: BSL-2 • Francisella tularensis: BSL-2 • Vibrio cholerae: BSL-2 • Staphylococcus aureus: BSL-2 • Escherichia coli K12 or derivative: BSL-1 • Escherichia coli K12 or derivative: BSL-1 • Klebsiella pneumoniae: BSL-2 • Klebsiella pneumoniae: BSL-2 • Pseudomonas aeruginosa: BSL-2 • Escherichia coli K12 or derivative: BSL-2 • A-549: BSL-1 • HEP-G2: BSL-1 • 293T: BSL-2

	• Francisella tularensis: BSL-2 • Burkholderia cepacia: BSL-2 • Human Derived Blood and Blood Types: BSL-2 • Respiratory Tissue: BSL-2 • Non Human Derived Blood and Blood Types: BSL-2 • HekBlue hTLR4 reporter cells: BSL-1 • Burkholderia thailandensis: BSL-1 • Enterobacter cloacae complex: BSL-2
Applicable NIH Guidelines:	• Section III-D-1-a • Section III-F • Section III-F-1 • Section III-D

a. **Determination:** Modifications Required
Move: Lane Coffee
Second: Judy Hecker

b. **Required modifications:**
1. Recombinant or Synthetic Nucleic Acid Work Description – Spectinomycin and Kanamycin were noted as antibiotics for which a K. pneumoniae infection are treated clinically. Need clarification if this work involves antibiotic resistance to clinically useful prophylactic or therapeutic interventions. If it does, this protocol would fall within the Dual Use Research of Concern.

c. **Votes:**

For:	9
Against:	0
Recused:	0
Absent:	1
Abstained:	0

Initial Protocol

4. Review of SPROTO202500000011

Title:	Long-Term Health Impacts - Koszalinski
Investigator:	Rebecca Koszalinski
Submission ID	SPROTO202500000011
Funding:	• Name: Florida Department of Health, Grant Office ID: AWD00006659, Funding Source ID: CODVK
Documents Reviewed:	• 2024-2025 SOP Biorepository • 2024-2025 SOP Pack and Ship

	• 20204-2025 SOP Destruction • 2024-2025 SOP Collection
Agents:	• Human Derived Blood and Blood Types • Nasal secretions • Urine
Agent Containment:	Biological Containment Levels: • Urine: BSL-1 • Nasal secretions: BSL-1 • Human Derived Blood and Blood Types: BSL-2
Applicable NIH Guidelines:	None

a. **Determination:** Modifications Required
Move: Judy Hecker
Second: Yulia Gerasimova

b. **Required modifications:**
1. Summary of Research – Need description of work flow
2. Tissues, Blood, and Body Fluids –
   a. Human Derived Blood… - who is the supplier of the blood? Penn State; Lab District and Greenwater Labs seem to be where the blood is being sent to for analysis. Who is drawing the blood and is there an IRB protocol.
3. Exposure Assessment and Protective Equipment – Question 1; What is the documentation which verifies the blood, urine and nasal samples are Pathogen Free? Do you have something from the supplier?

c. **Votes:**

For:	9
Against:	0
Recused:	0
Absent:	1
Abstained:	0

REVIEW OF OTHER AGENDA ITEMS

None